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Introduction
Gene expression is tightly controlled, frequently requiring co­
ordinated regulation between chromatin remodeling, chromatin 
modifications, and the activities of transcription factors. Deter­
mination of the myogenic lineage and differentiation of skeletal 
muscle cells are precisely orchestrated by the MyoD family of 
basic helix­loop­helix proteins (Weintraub et al., 1991; Molkentin 
and Olson, 1996; Arnold and Winter, 1998; Tapscott, 2005). 
The ability of MyoD to convert cells of many different lineages 
and differentiation states to skeletal muscle suggests that MyoD 
can both access genes in a repressive chromatin context and ac­
tively remodel the appropriate loci independent of cell lineage 
or differentiation state.
Chromatin  modification  events,  which  include  histone 
acetylation, methylation, phosphorylation, and ubiquitination, 
are  central  to  the  regulation  of  gene  expression  (Klose  and 
Zhang,  2007;  Ruthenburg  et  al.,  2007).  Histone  acetyltrans­
ferases were shown to interact with MyoD and acetylate pro­
moter histones as well as MyoD itself (Sartorelli et al., 1999; 
Polesskaya et al., 2000; Berkes and Tapscott, 2005). Histone 
acetyltransferases  with  the  subsequent  recruitment  of  SWI 
(switch)–SNF (sucrose nonfermentable) complexes positively 
regulate MyoD activity at the onset of skeletal muscle differ­
entiation (Berkes and Tapscott, 2005; Forcales and Puri, 2005; 
Sartorelli and Caretti, 2005). In contrast, histone deacetylases 
condense chromatin and inhibit the accessibility of transcription 
factors to regulatory elements (promoters and/or enhancers) of 
their target genes and, thereby, repress gene expression (McKinsey   
et al., 2001). Similar to the acetylation and deacetylation pro­
cess, modification of histones by methylation and demethylation 
also plays an important role in the activation of gene expres­
sion (Klose and Zhang, 2007). Globally, the levels of mono­   
and dimethylation of histone H3 at lysine 4 (H3­K4m1 and   
H3­K4m2, respectively) correlate with gene transcriptional levels 
(Barski et al., 2007). Suv39h1, a histone H3 lysine 9 (H3­K9) 
methyltransferase  associated  with  transcriptional  silencing 
(Kouzarides, 2002; Sims et al., 2003), has been demonstrated 
to associate with MyoD on the promoters of muscle genes, 
T
he molecular events that modulate chromatin struc-
ture during skeletal muscle differentiation are still 
poorly  understood.  We  report  in  this  paper  that 
expression of the H3-K4 histone methyltransferase Set7 
is increased when myoblasts differentiate into myotubes   
and  is  required  for  skeletal  muscle  development,  ex-
pression of muscle contractile proteins, and myofibril 
assembly. Knockdown of Set7 or expression of a dominant- 
negative  Set7  mutant  impairs  skeletal  muscle  differ-
entiation, accompanied by a decrease in levels of histone 
monomethylation  (H3-K4me1).  Set7  directly  interacts 
with MyoD to enhance expression of muscle differentia-
tion genes. Expression of myocyte enhancer factor 2 and 
genes encoding contractile proteins is decreased in Set7 
knockdown myocytes. Furthermore, we demonstrate that 
Set7 also activates muscle gene expression by precluding 
Suv39h1-mediated  H3-K9  methylation  on  the  promot-
ers of myogenic differentiation genes. Together, our ex-
periments define a biological function for Set7 in muscle 
differentiation and provide a molecular mechanism by 
which  Set7  modulates  myogenic  transcription  factors 
during muscle differentiation.
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affects skeletal muscle development. Our experiments therefore 
establish a central role of Set7 in muscle gene expression and 
skeletal muscle development.
Results
Increased expression of Set7 during 
skeletal muscle differentiation
We examined the expression of Set7 in different adult mouse 
tissues. RT­PCR analysis showed that Set7 is expressed in all 
tissues tested, including skeletal muscle (Fig. 1 A). We next   
investigated the potential change of Set7 expression during 
muscle differentiation. C2C12 myoblasts are a well­established 
cell line that can faithfully mimic skeletal muscle differentia­
tion in vitro, as indicated by the terminal differentiation and 
expression of muscle differentiation marker genes, upon serum 
withdrawal (Blau et al., 1985; Soulez et al., 1996; Lu et al., 
2000; Chen et al., 2006). RT­PCR and Western blot analyses 
demonstrate that the expression level of both Set7 transcript 
and  protein  increases  during  C2C12  differentiation  (Fig.  1,   
B and C), occurring in parallel with increased expression of the 
muscle differentiation markers myogenin and myosin heavy 
chain (MHC; Fig. 1, B and C). Together, these data demon­
strate that the expression of Set7 is dynamically regulated dur­
ing normal skeletal muscle differentiation, suggesting a role in 
skeletal muscle development.
Set7 is required for the terminal 
differentiation of skeletal  
muscle myoblasts
To study the potential function of Set7 in skeletal muscle cell 
differentiation, we first overexpressed Set7 in C2C12 myoblasts. 
We cotransfected a pcDNA­Set7 expression plasmid and a con­
trol plasmid encoding GFP into C2C12 myoblasts. Cells were 
then either maintained in growth medium or switched into differ­
entiation medium after transfection (see Materials and methods). 
Unexpectedly, overexpression of Set7 did not appear to affect 
muscle differentiation, as there was no observable morpho­
logical difference between Set7 and control GFP­transfected 
cells (Fig. 2 A). Furthermore, there were no detectable changes 
in the expression of early and late myogenic markers, including 
MyoD, myogenin, and MHC, in Set7­transfected cells (Fig. 2, 
B–D; and Table I). In addition, myoblast proliferation was not 
affected by Set7 overexpression, as indicated by the observa­
tion  that  the  expression  level  of  phosphorylated  histone  H3 
(phospho–histone H3), a marker for cell proliferation, was not 
changed (Fig. 2, C and D; and Table I). When MyoD was used 
as a positive control in those experiments, it significantly pro­
moted myoblast differentiation and the expression of myogenic 
differentiation marker genes (unpublished data).
Next, we tested the effect of a Set7 H297G mutant on 
C2C12 myoblast differentiation. The Set7 H297G mutant con­
tains a point mutation within its SET domain and was previ­
ously shown to function as a dominant­negative mutant (Wang 
et al., 2001; Nishioka et al., 2002). When C2C12 myoblasts were 
transfected with the Set7 H297G dominant­negative mutant (here­
after referred to as Set7­dn in this study), myogenic differentiation 
resulting in transcriptional inhibition in proliferating myoblasts 
(Mal, 2006).
Set7, also known as Set9, is a SET domain–containing his­
tone 3 lysine 4 (H3­K4) methyltransferase (Wang et al., 2001; 
Nishioka et al., 2002). Set7 is known to stimulate activator­ 
induced transcription in vivo (Nishioka et al., 2002; Kouskouti 
et al., 2004), indicating that its activity is likely modulated or 
associated with other factors. Set7 converts unmodified H3­K4 
into monomethylated H3­K4 but is incapable of further methyl­
ation using monomethylated H3­K4 as a substrate (Kouzarides, 
2002; Xiao et al., 2003; Couture and Trievel, 2006). Intrigu­
ingly, the methylation of H3­K4 by Set7 and the methylation of 
H3­K9 by Suv39h1 are mutually exclusive (Wang et al., 2001; 
Nishioka et al., 2002). Furthermore, Suv39h1 and the associ­
ated methylation at myogenic loci suppress MyoD­mediated 
myogenic  differentiation  (Mal,  2006).  We  hypothesize  that 
Set7 and the associated methylation of H3­K4 promote MyoD­ 
mediated  myogenic  differentiation  by  suppressing  Suv39h1­
mediated transcriptional repression.
Herein, we show that Set7 physically interacts with MyoD 
on myogenic promoters to activate muscle gene expression. 
siRNA knockdown of Set7 or overexpression of a dominant­
negative Set7 mutant impaired MyoD­mediated muscle differ­
entiation. Consistent with these observations, knockdown the 
expression of endogenous Set7 in zebrafish embryos dramatically 
Figure 1.  The expression of Set7 is increased during skeletal muscle dif-
ferentiation. (A) RT-PCR analyses of Set7 expression using RNAs isolated 
from adult mouse tissues as indicated. GAPDH was used as a loading 
control. (B) RT-PCR analyses of the expression of Set7 and skeletal muscle 
(Sk  muscle)  -actin  (SK--Actin)  using  total  RNA  isolated  from  C2C12 
myoblasts cultured in differentiation medium for 0, 1, 3, 5, 7, and 10 d   
(D0–D10). GAPDH was used as a loading control. (C) C2C12 myoblasts 
were cultured in differentiation medium for 0, 1, 3, 5, 7, and 10 d. Western 
blot analyses were performed with cell extracts using antibodies that recog-
nize the indicated proteins. -Tubulin was used as a loading control.553 Set7 in skeletal muscle • Tao et al.
Muscle  creatine  kinase  (MCK)  expression  is  induced 
during skeletal muscle myoblast differentiation. It has been 
well documented that the transcription of the MCK gene is 
MyoD dependent (Lassar et al., 1989). We therefore tested whether 
Set7 or Set7­dn could affect MyoD­dependent transactivation of 
was dramatically inhibited, as there were fewer myotubes formed 
in  Set7­dn–transfected  C2C12  cultures  (Fig.  2  A).  Molecular 
marker analysis confirmed that the expression of myogenic dif­
ferentiation marker genes was substantially inhibited in Set7­dn– 
transfected cells (Fig. 2, B–D; and Table I).
Figure 2.  Set7 affects skeletal muscle myoblast proliferation and differentiation. (A) C2C12 myoblasts were transfected with Set7 or a dominant-negative 
mutant of Set7 (Set7-dn) together with a GFP expression construct. Cells were transferred to differentiation medium for 72 h, and myoblast differentiation 
was observed by fluorescent microscopy. The quantitative analysis result of the mean myotube numbers from 10 randomly chosen microscopic fields was 
presented on the right. Data represent the means ± SD from at least three independent experiments. Bar, 30 µm. ***, P < 0.001. (B) C2C12 myoblasts 
were transfected with Set7 or Set7-dn. Cells were transferred to differentiation medium for the indicated time, and the expression of myogenic differentiation 
genes was assayed by RT-PCR. GAPDH was used as a loading control. (C) C2C12 myoblasts were transfected with Set7 or Set7-dn. Cells were transferred 
to differentiation medium for the indicated time, and expression of myogenic differentiation proteins was assayed by Western blot analysis. -Tubulin was 
used as a loading control. (D) C2C12 myoblasts were transfected with Set7 or Set7-dn. Cells were transferred to differentiation medium for the indicated 
time, and myocyte proliferation and differentiation were assayed by immunostaining with the indicated antibodies. Phos H3, phospho–histone H3; MHC, 
myosin heavy chain. Bar, 20 µm. (E) The MCK promoter luciferase reporter (MCK-Luc) was cotransfected with a MyoD expression plasmid together with 
an increasing amount of Set7 or the Set7-dn expression plasmid. Luciferase activity was determined 48 h after transfection and was presented as relative 
luciferase activity in which the control was assigned a value of 1. Data represent the means ± SD from at least three independent experiments in duplicate. 
SK, skeletal muscle; MCK, muscle creatine kinase; D0, day 0. *, P < 0.05; **, P < 0.01.JCB • VOLUME 194 • NUMBER 4 • 2011   554
However, when both MyoD and the Set7­dn mutant were over­
expressed, MyoD­mediated myogenic conversion was repressed, 
as indicated by reduced myotube formation (Fig. 4 A). Quanti­
tative analyses of MHC­positive cells further support the view 
that the Set7­dn mutant impaired MyoD­mediated myogenic 
conversion (Fig. 4 B). In addition, Western blot analysis dem­
onstrates a significant decrease in the MHC protein expression 
in Set7­dn–transfected cells (Fig. 4 C). Consistent with our ob­
servations using the Set7­dn mutant, MyoD­mediated myogenic 
differentiation is significantly impaired, as is MHC expression,   
when  endogenous  Set7  expression  is  repressed  by  siRNA   
(Fig. 4, D and E). Together, these results suggest that Set7 plays 
an important role in MyoD­mediated myogenic induction and 
muscle gene expression.
Set7 directly interacts with MyoD
MyoD has been shown to interact with many transcription fac­
tors  and  other  transcriptional  modulators  to  control  muscle 
gene expression and muscle differentiation (Tapscott, 2005). 
We next tested whether Set7 physically interacts with MyoD.   
We first applied GST fusion protein pull­down assays to de­
termine the interaction between Set7 and MyoD. Glutathione 
beads containing bacterially expressed GST­Set7, GST–Set7­dn   
fusion proteins, or control GST protein alone were incubated 
with HEK293T cell nuclear extracts in which the Myc­MyoD 
was  overexpressed.  Subsequent  Western  blot  analysis  using   
anti­Myc  antibodies  demonstrated  that  both  Set7  and  the   
Set7­dn mutant proteins directly interact with MyoD (Fig. 5 A). 
We further confirmed the interaction between Set7 and MyoD 
by coimmunoprecipitation (IP; co­IP) experiments with ectopi­
cally expressed proteins from HEK293T cells (Fig. 5 B).
The expression of Set7 and MyoD at the protein level 
increases  when  myoblasts  are  induced  to  differentiate  into 
myotubes (Figs. 1 C and 5 C). We therefore examined whether 
endogenous Set7 and MyoD proteins interact in C2C12 myo­
blasts  and  myotubes.  Co­IP  experiments  clearly  show  that 
Set7 interacts with endogenous MyoD in C2C12 cells. Most 
importantly, their interaction is enhanced during skeletal mus­
cle differentiation (Fig. 5 C), which may be caused by, at least 
in part, the increased expression levels of MyoD and Set7. 
Together, these data demonstrate that Set7 and MyoD physi­
cally interact, which further suggests that this interaction con­
tributes to the regulation of skeletal muscle gene expression 
and myoblast differentiation.
the MCK gene. We cotransfected C2C12 myoblasts with a 
MCK  promoter  luciferase  reporter  gene  and  an  expression 
plasmid  encoding  MyoD  along  with  (or  without)  different 
amounts of Set7 or the Set7­dn mutant. Set7 or Set7­dn alone 
did not significantly affect the expression of the MCK pro­
moter luciferase reporter. Cotransfection of Set7 had no obvi­
ous effect on the expression of MyoD­activated MCK luciferase 
reporter gene (Fig. 2 E). However, the Set7­dn mutant caused 
about a twofold suppression of MyoD­activated MCK lucif­
erase  reporter  gene  expression  (Fig.  2  E).  Together,  these   
data suggest that Set7 is a critical factor necessary for myo­
blast differentiation.
To confirm the aforementioned observations, we performed 
additional independent experiments wherein we knocked down 
endogenous Set7 in C2C12 myoblasts using siRNAs. We trans­
fected Set7 siRNA or control scrambled siRNA into C2C12 
myoblasts before differentiation (see Materials and methods). 
Set7 siRNA, but not the control siRNA, dramatically knocked 
down the endogenous Set7 protein level (Fig. 3 C). After 3 d   
of  differentiation,  myogenic  differentiation  was  impaired  in 
Set7 siRNA­transfected cells but not in control cells (Fig. 3, 
A and B). Consistent with the results from the Set7­dn over­
expression experiments, knockdown of Set7 by siRNA repressed 
the expression of myogenic differentiation genes: MyoD, myo­
genin,  myocyte  enhancer  factor  2  (MEF2),  and  MHC.  We 
therefore conclude that Set7 is necessary for myogenic differ­
entiation of skeletal muscle myoblasts. Conversely, cell prolif­
eration appears slightly enhanced in Set7 siRNA­transfected   
myoblasts, as indicated by an increase in phospho–histone H3 
level (Fig. 3 C).
Set7 is required for MyoD to convert 
fibroblasts into myoblasts
MyoD is able to convert nonmuscle cells into myoblasts when 
ectopically  overexpressed  (Weintraub  et  al.,  1989).  We  ex­
amined whether Set7 could affect MyoD­mediated myogenic 
conversion  in  10T1/2  fibroblasts.  When  10T1/2  fibroblasts 
were transfected with a MyoD expression plasmid, cells were 
converted  into  myoblasts  after  switching  into  differentiation 
medium. Set7 by itself did not affect myogenic conversion of 
10T1/2 fibroblasts, and neither did it affect cellular prolifera­
tion nor differentiation (unpublished data). When both MyoD 
and  Set7  were  overexpressed  in  10T1/2  fibroblasts,  Set7   
did not appear to affect MyoD­mediated myogenic conversion.   
Table I.  Effect of Set7 and the Set7-dn mutant on myoblast proliferation and differentiation
Treatment Growth medium Differentiation medium at 24 h Differentiation medium at 48 h
Phospho-H3–positive 
cells
Phospho-H3–positive 
cells
Myogenin-positive cells Myogenin-positive cells MHC-positive cells
Total  
number
Relative to 
control
Total  
number
Relative to 
control
Total  
number
Relative to 
control
Total  
number
Relative to 
control
Total  
number
Relative to 
control
% % % % %
pcDNA 94 100.0 59 100.0 197 100.0 363 100.0 120 100.0
Set7 92 97.9 62 105.1 193 98.0 370 101.9 113 94.2
Set7-dn 135 143.6 95 161.0 142 72.1 309 85.1 81 67.5555 Set7 in skeletal muscle • Tao et al.
Figure 3.  Knockdown of Set7 impairs skele-
tal muscle myocyte differentiation. (A) C2C12 
myoblasts were transfected with control siRNA 
or siRNA against Set7 together with a GFP 
expression  construct.  Cells  were  transferred 
to differentiation medium for 72 h, and myo-
blast  differentiation  was  observed  under  a 
fluorescent microscope. Bar, 40 µm. (B) The 
quantitative analysis result of the mean myo-
tube numbers from 10 randomly chosen micro-
scopic fields. Data represent the means ± SD 
from at least three independent experiments. 
si, siRNA. ***, P < 0.001. (C) C2C12 myo-
blasts were transfected with control siRNA or 
siRNA against Set7. Cells were transferred to 
differentiation medium for the indicated time, 
and  Western  blot  analyses  were  performed 
using antibodies that recognize the indicated 
proteins.  -Tubulin  was  used  as  a  loading 
control. Phos H3, phospho–histone H3; MHC, 
myosin heavy chain; Crtl., control. Black lines 
indicate  that  intervening  lanes  have  been 
spliced out.
To determine the regions/domains of Set7 and MyoD that 
mediate their interaction, we performed additional GST protein 
pull­down and co­IP experiments with multiple Set7 and MyoD 
truncation mutants. The Set7 protein contains a conserved SET 
domain in its C terminus (Fig. 5 D). Although both full­length 
Set7 and the Set7­dn mutant interact with MyoD (Fig. 5 B), the 
N­terminal regions of Set7 without the SET domain (aa 1–212) 
appeared to bind to MyoD with higher affinity (Fig. 5 D), sug­
gesting that the SET domain may have a negative effect on the 
interaction of Set7 and MyoD. Consistent with this notion, we 
found that the SET domain alone (aa 212–343) failed to bind to 
MyoD (Fig. 5 D). Our findings are consistent with the view that 
the N­terminal region of Set7 serves as its protein–protein inter­
action domain, as has been previously determined structurally 
(Xiao et al., 2003).
MyoD  belongs  to  the  basic  helix­loop­helix  family  of 
transcription factors, and it contains several domains that medi­
ate  the  interactions  with  other  proteins  (Fig.  5  E;  Tapscott, 
2005). We constructed MyoD deletion mutants and tested their 
ability for Set7 binding. Co­IP experiments demonstrate that 
both the N­ and C­terminal regions of MyoD are required for its 
interaction with Set7 (Fig. 5, E and F). Additional co­IP experi­
ments  demonstrate  that  both  the  C/H  (cysteine­histidine)   
domain (aa 63–99) and the helix III domain (aa 245–258) of 
MyoD are required for its interaction with Set7. In contrast, de­
letion of the basic (aa 102–135) or the helix­loop­helix domain 
(aa 143–162) was found to have no effect on the interaction 
with Set7 (Fig. 5, E and F; and not depicted). These results indi­
cate that the C/H and helix III domains of MyoD mediate its inter­
action with Set7.JCB • VOLUME 194 • NUMBER 4 • 2011   556
Figure 4.  Set7-dn mutant inhibits MyoD-mediated conversion of 10T1/2 fibroblasts into myoblasts. (A) 10T1/2 fibroblasts, which stably expressed Set7 
or the Set7-dn mutant, were transiently transfected with a MyoD expression plasmid. Cells were then transferred to differentiation medium for 72 h, and 
myogenic conversion was scored by positive staining for MHC expression (red). DAPI counter stains the nucleus. (B) The result of quantitative analysis 
was presented as a percentage of nuclei in myotubes from 10 randomly chosen microscopic fields. Data represent the means ± SD from at least three 
independent experiments. (C) 10T1/2 fibroblasts, which stably expressed Set7 or the Set7-dn mutant, were transiently transfected with a MyoD expression 
plasmid. Cells were then transferred to differentiation medium for 72 h, and myogenic conversion was determined by Western blot analysis for the MHC 
protein. The expression levels of Set7 and Set7-dn proteins are indicated. -Tubulin was used as a loading control. (D) 10T1/2 fibroblasts were transfected 
with control siRNA or siRNA against Set7 together with a MyoD expression plasmid. Cells were then transferred to differentiation medium for 72 h, and   
myogenic conversion was scored by positive staining for MHC expression (red). DAPI counter stains the nucleus. (E) 10T1/2 fibroblasts were trans-
fected with control siRNA or siRNA against Set7 together with a MyoD expression plasmid. Cells were then transferred to differentiation medium for 72 h, and 
myogenic conversion was analyzed by Western blot analysis using antibodies that recognize the indicated proteins. -Tubulin was used as a loading 
control. Crtl., control. Bars, 40 µm.557 Set7 in skeletal muscle • Tao et al.
H3­K4 (Wang et al., 2001; Nishioka et al., 2002; Francis et al., 
2005; Callis et al., 2008). We investigated whether Set7 asso­
ciates with chromatin at the promoters/enhancers of skeletal 
muscle differentiation genes and, if so, whether such an associ­
ation alters H3­K4 methylation during myoblast differentiation.   
Set7 is required for MyoD to associate 
with the promoters/enhancers of muscle 
differentiation genes
Set7 is a histone methyltransferase suggested to influence gene 
expression, at least partially, by modifying local chromatin at 
Figure 5.  Set7 and MyoD interact in vitro and in vivo. (A) MyoD specifically interacted with GST-Set7 and GST–Set7-dn, but not with GST alone, in GST 
pull-down assays. Coomassie-stained proteins corresponding to relative amounts of GST and GST-Set7 proteins used in the pull-down assay are shown.   
(B) HEK293T cells were transfected with Flag-tagged Set7 and/or Myc-tagged MyoD as indicated. (top) Set7 proteins were immunoprecipitated by anti-
Flag antibodies, and anti-Myc antibodies were used to detect the presence of MyoD proteins in the immunoprecipitates by Western blot analysis. (bottom) 
One fifteenth of cell extracts were directly immunoblotted to detect the presence of Set7 and MyoD proteins. (C) Cell extracts from C2C12 myocytes at 
indicated differentiation dates (0, 1, or 3 d [D0, D1, and D3]) were immunoprecipitated using anti-Set7 antibodies (or IgG in controls), and the presence 
of MyoD proteins in the immunoprecipitates were detected by anti-MyoD antibodies. The expression of Set7 and MyoD was demonstrated in Western 
blot analysis. -Tubulin was used as a loading control. (D, top) Schematic diagram of Set7 mutants for MyoD interaction. The arrowhead in indicates the 
Set7 point mutation that created the Set7-dn. (bottom) Myc-tagged MyoD was detected in Flag-Set7 aa 1–212 and aa 1–343, but not in aa 212–343 
immunoprecipitates. (E) Schematic diagram of MyoD mutants for the Set7 interaction. (F) Myc-tagged MyoD mutants were cotransfected with Flag-tagged 
Set7, and their interaction was detected in Flag-Set7 immunoprecipitates. IB, immunoblot; HLH, helix-loop-helix.JCB • VOLUME 194 • NUMBER 4 • 2011   558
H3­K4 monomethylation on the promoters/enhancers of myo­
genic differentiation genes (Fig. 6 C). Association of Set7 with 
the  promoter/enhancer  regions  of  myogenic  differentiation 
genes as well as the H3­K4 monomethylation was unchanged 
in the presence of the scrambled control siRNA, further demon­
strating the specificity of the Set7 siRNA (Fig. 6 C).
Our results establish that Set7 is required for proper myo­
blast differentiation (Figs. 2 and 3). We demonstrate that Set7 
and MyoD physically interact (Fig. 5), suggesting that Set7 may 
achieve its biological function through modulation of MyoD. 
We therefore investigated whether Set7 is required for MyoD to 
associate with the regulatory regions of myogenic differentia­
tion genes. Results from ChIP experiments demonstrate that 
depletion of Set7 by siRNA treatment abolishes the association 
of MyoD with the promoters/enhancers of myogenic differenti­
ation genes in differentiated myotubes (Fig. 6 D). Our results 
suggest that Set7 is required for MyoD to bind to the regulatory 
region of muscle differentiation genes to activate gene expres­
sion and to initiate the myogenic differentiation process. Of 
note, MyoD expression level was decreased in Set7 knockdown 
cells, which may also contribute to the decreased MyoD binding   
to the promoters/enhancers.
We first performed chromatin IP (ChIP) assays using antibodies 
specific for Set7 and monomethylated H3­K4. After cross­ 
linking, immunoprecipitated DNA fragments bound by proteins 
were then detected by semiquantitative PCR using specific prim­
ers spanning the regulatory regions of myogenic differentiation 
genes, including MyoD, myogenin, MHC, and MCK (Fig. 6 B).   
Indeed, Set7 associated with the regulatory regions of myo­
genic differentiation genes on chromosomes, which were also 
monomethylated at H3­K4 (Fig. 6 C). Furthermore, both the 
Set7 association and the H3­K4 monomethylation status on the 
promoters/enhancers  of  myogenic  differentiation  genes  sub­
stantially increased during myogenic differentiation (Fig. 6 C).
Next, we examined whether knockdown of endogenous 
Set7 in C2C12 myoblasts could impact H3­K4 monomethyl­
ation status on the promoters/enhancers of myogenic differen­
tiation genes. We achieved near complete knockdown of the 
endogenous Set7 protein by siRNA treatments (Fig. 6 A). As 
expected, the association of Set7 with the regulatory regions 
of myogenic differentiation genes was completely abolished 
when  Set7  was  knocked  down  in  differentiated  myotubes   
(Fig. 6 C). Consistent with the role of Set7 in H3­K4 mono­
methylation, knockdown of Set7 also dramatically decreased 
Figure 6.  Set7 is required for MyoD to bind to the promoters/enhancers of skeletal muscle differentiation genes. (A) C2C12 myoblasts were transfected 
with control siRNA or siRNA against Set7. Cells were transferred to differentiation medium for the indicated times and Western blot analyses were per-
formed with cell extracts using antibodies that recognized Set7 proteins. -Tubulin was used as a loading control. (B) Schematic diagrams of promoter or 
enhancer regions of indicated myogenic differentiation genes. Arrows indicate PCR primers used for the PCR reaction. (C) IPs were performed with anti-Set7 
and anti–H3-K4 antibodies as indicated. (D) IPs were performed with anti-MyoD antibodies. (C and D) The amount of DNA in each sample (input) is shown. 
IPs performed with IgG were used as controls. GAPDH was used as a loading control. Myog, myogenin; Crtl. control; D0, day 0.559 Set7 in skeletal muscle • Tao et al.
Injection of Set7 MO, but not the control MO, led to 
a block of pre­mRNA splicing, as indicated by a band shift 
after  gel  electrophoresis  of  RT­PCR  products  (Fig.  7  A).   
Interestingly,  the  gross  morphology  of  Set7  MO­injected   
embryos (Set7 morphants) appears to be normal when com­
pared with controls (Fig. 7 B). However, all morphant embryos 
are paralyzed and fail to respond to tactile stimuli (unpublished 
data), suggesting a defect in musculature function. Immuno­
histochemistry analysis revealed that Set7 morphants exhibit 
a  dramatic  decrease  in  the  expression  of  the  MHC  protein   
(Fig. 7 C). Further analyses using antibodies that specifically 
label fast and slow MHCs demonstrate that both fast and slow 
MHC were dramatically decreased in Set7 morphant embryos   
(Fig. 7, D and E).
Our in vitro experiments showed that the expression of 
MEF2  was  down­regulated  in  Set7  knockdown  myoblasts.   
Interestingly, Hinits and Hughes (2007) recently reported that 
disruption of MEF2 expression in zebrafish leads to defects in 
Set7 is required for skeletal muscle 
development and myofiber assembly in vivo
The Set7 protein is highly conserved, and homologues for the 
mouse Set7 gene have been identified in species from zebrafish to 
human. Using the BLASTp (basic local alignment search tool for 
proteins) algorithm, we found that the zebrafish Set7 (NCBI   
Protein database accession no. NP_001002456) and mouse Set7 
(NCBI Protein database accession no. NP_542983) share 72% 
identity at the amino acid level (unpublished data). Therefore, to 
assess the function of Set7 during skeletal muscle development in 
vivo, we used the zebrafish model system in which gene expres­
sion and function can be specifically inhibited by morpholino 
oligomers (MOs) during embryonic development. Morpholinos 
can either bind to the 5 untranslated region of mRNAs to block 
translational process or interfere with pre­mRNA–splicing steps. 
We  designed  morpholino  oligomers  to  block  the  splicing  of   
zebrafish Set7 pre­mRNA, as this approach will allow us to con­
veniently monitor the splice modification events by RT­PCR.
Figure 7.  Set7 is required for skeletal muscle development and myofibril assembly. Zebrafish embryos were injected with control (CTRL) or Set7 morpho-
lino (MO) at the single-cell stage, and embryos were collected 24 h after fertilization. (A) RT-PCR analysis of zebrafish Set7 transcripts from control and 
Set7 morpholino embryos. Mutant (Mut) and wild-type (Wt) transcripts are indicated. (B) Bright-field embryonic images of control and Set7 morpholino. 
(C) Set7 morphants display defects in myofibril assembly as indicated by MHC immunostaining. Higher magnification is shown on the right. DAPI counter 
stains the nucleus. Bars, 60 µm. (D) Set7 morphants display defects in fast MHC expression. (E) Set7 morphants display defects in slow MHC expression. 
(F) MEF2 protein expression level was significantly decreased in Set7 morphants. Bar, 30 µm.JCB • VOLUME 194 • NUMBER 4 • 2011   560
the structure of skeletal muscles in control and Set7 morphants   
using  transmission  electron  microscopy.  As  seen  in  Fig.  8  A, 
there  are  significantly  fewer  and  shorter  myofibrils  in  Set7 
morphants as compared with controls. Close examination of 
myofiber sarcomeres revealed periodic absent z lines (Fig. 8 B,   
arrow) and noticeably narrower sarcomeres as compared with 
control (Fig. 8 B). In addition, an increased frequency of   
A­band branching is observed in Set7 morphants (Fig. 8 B, 
arrow). Together, these data demonstrate that Set7 is required 
for normal development of skeletal muscle and the assembly 
of myofibrils.
muscle  development  and  myofibril  assembly,  including  per­
turbed MHC expression, a phenotype very similar to what we 
observed in our Set7 morphants. We therefore examined the 
expression of MEF2 by immunostaining. Indeed, we found that 
MEF2 is significantly decreased in Set7 morphants (Fig. 7 F), 
indicating that the MEF2 family of transcription factors is likely 
involved in Set7­mediated regulation of muscle development 
and myofibril assembly.
The  aforementioned  observations  suggest  that  Set7  is 
required  for  the  proper  expression  of  myogenic  contractile 
proteins and the assembly of myofibrils. We next examined 
Figure 8.  Set7 morpholino-treated zebrafish 
exhibit impaired sarcomerogenesis and mor-
phological  defects  in  skeletal  muscle.  Trans-
mission  electron  microscopy  examinations 
of control or Set7 morphant skeletal muscle. 
(A) Set7 MO treatment results in morphologi-
cally altered myocytes with fewer and shorter 
myofibrils  as  compared  with  control.  Bars,   
10 µm. (B) Higher magnification reveals peri-
odic absent z lines (arrow) and noticeably nar-
rower sarcomeres as compared with control. 
An increased frequency of A-band branching 
(arrow) is observed with morpholino treatment. 
Bars, 500 nm. Images are representative of 
dorsal skeletal myocytes from n = 3 fish for 
both control and Set7 morphants.561 Set7 in skeletal muscle • Tao et al.
derived from wild­type or Suv39h
/ animals were transfected 
with  a  MyoD  expression  plasmid  and  were  subsequently 
switched to differentiation medium. Although MyoD is able to 
convert wild­type MEFs into MHC­positive myoblasts (albeit 
with lower efficiency when compared with that of 10T1/2 fibro­
blasts), there is a substantial increase in MHC­positive myo­
blasts  from  MyoD­transfected  Suv39h
/  MEFs  (Fig.  9  D). 
These results are consistent with a previous study in which 
Suv39h1 was shown to repress MyoD­mediated myogenic dif­
ferentiation (Mal, 2006). Loss of Suv39h proteins in Suv39h
/ 
MEFs does not appear to affect the expression level of the Set7 
transcript or protein (Fig. 9, E and F). H3­K4 protein expression 
in Suv39h
/ MEFs is indistinguishable from that of wild­type 
MEFs (Fig. 9 F). Together, these data clearly demonstrate that 
Set7 controls the H3­K4 monomethylation status at the promot­
ers/enhancers of myogenic differentiation genes. Our results 
also suggest that Set7 may influence the trimethylation status of 
H3­K9, at least in part, via inhibiting the function of Suv39h1, 
thereby modulating MyoD­mediated muscle differentiation   
and muscle gene expression (Fig. 9 G).
Discussion
In this study, we show that Set7 is necessary for skeletal muscle 
gene expression and myogenic differentiation. Knockdown of 
Set7 and the accompanying decrease in H3­K4 monomethyl­
ation  impairs  MyoD­mediated  muscle  differentiation.  Set7­
mediated H3­K4 monomethylation results in a decrease in the 
association of Suv39h1 as well as H3­K9 trimethylation at the 
promoter/enhancers  of  myogenic  differentiation  genes.  This 
evidence is further supported by in vivo experiments demon­
strating the role of Set7 in muscle development in zebrafish. 
Our findings provide insights into the molecular mechanism 
of how chromatin­remodeling enzymes work in concert with   
tissue­specific transcription factors to control muscle gene ex­
pression and muscle cell development.
MyoD functions as a central piece of a transcriptional net­
work for myogenic gene expression and has been shown to in­
teract with a variety of other transcriptional cofactors, including 
the  MEF2  family  of  transcription  factors  (Tapscott,  2005).   
Furthermore, MyoD transactivity is modulated by the chromatin 
status of its target genes (Tapscott, 2005). However, it is less 
clear how chromatin­remodeling enzymes and MyoD work in 
concert to direct myogenic gene expression.
Previous studies have shown that Set7­mediated histone 
methylation  may  function  in  transcriptional  activation  by   
competing with histone deacetylases or by precluding H3­K9 
methylation (Wang et al., 2001; Nishioka et al., 2002). In vitro, 
the methylations of H3­K4 by Set7 and of H3­K9 by Suv39h1 
were  shown  to  be  mutually  exclusive  (Wang  et  al.,  2001;   
Nishioka et al., 2002). A role for Suv39h1 in myogenesis was 
reported  in  which  Suv39h1  and  the  associated  methylation   
on myogenic loci suppressed MyoD­mediated myogenic dif­
ferentiation (Mal, 2006). It was further suggested that MyoD 
and  Suv39h1  physically  interact  in  a  manner  that  the  C/H   
domain, basic domain, and helix­loop­helix domain of MyoD 
are required.
Set7 competes with Suv39h1 for the 
binding of the promoters/enhancers of 
muscle genes
Set7 activates chromatin at the promoters and enhancers of its 
regulatory target genes, at least in part, by inhibiting Suv39h1­
mediated chromatin repression. Interestingly, the modifications 
of H3­K4 by Set7 and H3­K9 by Suv39h1, a H3­K9–specific 
methyltransferase, are mutually exclusive (Wang et al., 2001; 
Nishioka et al., 2002). Furthermore, it has been reported that 
Suv39h1 can interact with MyoD to repress myogenic differ­
entiation (Mal, 2006). We therefore tested whether Set7 could 
modulate the methylation status of H3­K9 and the association 
of  Suv39h1  with  the  promoters/enhancers  of  myogenic  dif­
ferentiation  genes.  We  first  examined  the  expression  levels 
of the Suv39h1 protein and the methylation status of H3­K4, 
H3­K9 in undifferentiated myoblasts, and differentiated myo­
tubes. Western blot analyses indicate that there is no substantial 
change in Suv39h1 protein expression level during muscle dif­
ferentiation (Fig. 9 A, compare lanes 1 and 3). Similarly, the 
levels of H3­K4 monomethylation and H3­K9 trimethylation 
are not changed during myoblast differentiation (Fig. 9 A, com­
pare lanes 1 and 3). We further examined the expression level 
of  additional  methyltransferases  in  Set7  knockdown  C2C12 
cells. As shown in Fig. 9 B, we found that the expression lev­
els of Ash1l (ash1 [absent, small, or homeotic]­like) and Prmt5 
(protein arginine methyltransferase 5) were not altered in Set7 
knockdown C2C12 cells.
Consistent with a previous study indicating that Suv39h1 
repressed  myogenic  gene  expression  (Mal,  2006),  our  ChIP   
results revealed that the association of Suv39h1 with the pro­
moters/enhancers of myogenic differentiation genes was sig­
nificantly decreased in differentiated myotubes (Fig. 9 C). This 
decrease is accompanied by a decrease in the trimethylation 
of H3­K9 (H3­K9me3) at the regulatory regions of myogenic 
differentiation  genes  (Fig.  9  C).  In  contrast,  H3­K4  mono­
methylation was substantially increased during muscle differ­
entiation (Fig. 9 C). Knockdown of Set7 by siRNAs did not 
affect Suv39h1 protein level or H3­K9 trimethylation, as demon­
strated by Western blot analyses (Fig. 9 A). However, the level 
of H3­K4 monomethylation was decreased (Fig. 9 A, lane 4). 
Interestingly, knockdown of Set7 results in an increase in the 
association of Suv39h1 with the promoters/enhancers of myo­
genic differentiation genes and a significant increase in H3­K9 
trimethylation  accompanied  by  a  decrease  in  H3­K4  mono­
methylation (Fig. 9 C). Our results therefore support the view 
that the modifications of H3­K4 by Set7 and H3­K9 by Suv39h1 
are  mutually  exclusive  on  the  promoters/enhancers  of  myo­
genic differentiation genes. Furthermore, these observations are 
consistent with a previous study demonstrating that Suv39h1­ 
mediated H3­K9 trimethylation represses muscle gene expression 
and inhibits skeletal muscle differentiation (Mal, 2006).
Genetic  deletion  of  Suv39h1  and  Suv39h2  in  mice 
(Suv39h
/) results in severe impairment of animal development 
and chromosomal stabilities (Peters et al., 2001). We therefore 
tested whether loss of Suv39h proteins could affect MyoD­ 
mediated myogenic conversion and myogenic gene expression 
in fibroblasts. Primary mouse embryonic fibroblasts (MEFs)   JCB • VOLUME 194 • NUMBER 4 • 2011   562
region of repressed chromatin as marked by the enrichment of   
H3­K9 methylation of histones in undifferentiated myoblasts 
(Mal and Harter, 2003). With the help of MyoD, Set7 can   
access  the  silencing  nucleosome  and  monomethylates  H3­
K4 at the myogenic regulatory regions, leading to increased   
affinity of MyoD to those regions. Conversely, MyoD failed 
to associate with the promoters/enhancers of myogenic dif­
ferentiation genes when Set7 was knocked down, resulting in 
myogenic repression (Fig. 9 G).
Consistent with the view that Set7 and Suv39h1 antago­
nize each other to regulate muscle differentiation, we found that 
MyoD­mediated myoblast conversion from fibroblasts was   
Our  observation  that  Set7  physically  interacts  with 
MyoD at both C/H and helix III domains is intriguing. These 
two domains have been shown to be necessary for MyoD to 
initiate  chromatin  remodeling  at  myogenic  loci,  thereby  al­
lowing the activation of a subset of specific muscle differen­
tiation genes (Gerber et al., 1997; Berkes et al., 2004). Given 
that the C/H domain is also required for MyoD to interact with 
Suv39h1 (Mal, 2006), we speculate that during skeletal mus­
cle differentiation, increased Set7 expression will compete with 
Suv39h1 for MyoD association. This will consequently lead to 
the occupation of MyoD at the promoters/enhancers of myo­
genic differentiation genes, which are normally located in a 
Figure 9.  Set7 antagonizes Suv39h1 to pro-
mote MyoD-mediated skeletal muscle myoblast 
differentiation.  (A)  C2C12  myoblasts  were 
transfected with control siRNA (Ctrl.) or siRNA 
against Set7. Cells were transferred to differ-
entiation medium for the indicated times, and 
Western blotting was performed with cell ex-
tracts using antibodies that recognize the indi-
cated proteins. -Tubulin was used as a loading 
control. (B) Methyltransferase gene expression 
during C2C12 differentiation. Quantitative RT-
PCR analysis of Ash1l, myogenin (Myog), Set7, 
and Prmt5 gene expression at day 0 (D0) and 
day 3 (D3) of differentiation with and without 
Set7 siRNA treatment (siSet7). Data represent 
the means + SD from three independent experi-
ments. *, P < 0.05. (C) IPs were performed with 
anti–H3-K4, anti–H3-K9, and anti-Suv39h1 anti-
bodies as indicated. The amount of DNA in each 
sample (input) is shown. IPs performed with IgG 
were used as controls. GAPDH was used as a 
loading control. (D) MEF cells from wild type 
(+/+) or Suv39h1/h2 double knockout (/) 
were transiently transfected with an expression 
plasmid for MyoD. Myogenic conversion was 
scored by positive staining for MHC expression 
(red) 6 d after differentiation induction. DAPI   
counter stains the nucleus (blue). Bar, 40 µm. 
The result of quantitative analysis, which was 
presented as the percentage of nuclei in myo-
tubes  from  10  randomly  chosen  microscopic 
fields, is presented on the right. Data represent 
the means ± SD from at least three indepen-
dent experiments. P = 0.002. (E) RT-PCR analy-
ses of the expression of Suv39h1, Suv39h2, 
and Set7 transcripts using total RNA isolated 
from  wild-type  (+/+)  or  Suv39h1/h2  double 
knockout (/) MEFs. GAPDH was used as a   
loading control. (F) Western blot analyses using   
antibodies  that  recognize  Set7  and  H3-K4 
proteins  from  cell  extracts  of  wild-type  (+/+) 
or Suv39h1/h2 double knockout (/) MEFs. 
-Tubulin was used as a loading control. (G) A 
working  model  to  account  for  the  molecular 
regulation  of  MyoD-mediated  skeletal  muscle 
differentiation, which is modulated by Set7 and 
Suv39h1. In undifferentiated myoblasts, MyoD is 
associated with Suv39h1/2 on the promoters/ 
enhancers  of  myogenic  differentiation  genes. 
Suv39h1-mediated H3-K9 methylation resulted 
in  condensation  of  chromatin  and  transcrip-
tional  repression.  During  skeletal  muscle  dif-
ferentiation,  increased  Set7  expression  will 
compete with Suv39h1 for MyoD association 
and H3-K4 methylation. This will consequently 
lead  to  the  occupation  of  MyoD  at  the  pro-
moters/enhancers  of  myogenic  differentiation 
genes, resulting in myogenic activation.563 Set7 in skeletal muscle • Tao et al.
same day of transfection (6 h after transfection) and defined it as day 0. 
Cells were switched to medium containing 2% horse serum to induce dif-
ferentiation, and samples were collected at the indicated dates. Myogen-
esis  was  monitored  by  either  cotransfecting  cells  with  a  pcDNA-GFP 
construct (Figs. 2 A and 3 A) using a reagent (Lipofectamine LTX; Invitro-
gen) or staining cells with myogenic markers. Cells that contain two or 
more nuclei were viewed as myotubes. The Suv39h-null MEFs were pro-
vided by T. Jenuwein (Max Planck Institute of Immunobiology and Epi-
genetics, Freiburg, Germany).
Generation of stable 10T1/2 cell lines
The PIG vector, PIG Set7, and PIG Set7-dn were transfected into 10T1/2 
cells  by  electroporation  with  the  Nucleofector  system  according  to  the 
manufacturer’s instruction (Lonza). Transfected cells were then plated on 
10-cm dishes overnight. On the next day, cells were placed in selection 
medium that contained 5 µg/ml puromycin for 10 d. Cells were pas-
saged, and selection medium was changed every other day.
siRNA knockdown
C2C12 myoblasts cultured in growth medium were transfected with con-
trol or Set7 siRNAs by electroporation with the Nucleofector system ac-
cording to the manufacturer’s instruction. 24 h later, cells were passaged 
and maintained in growth medium. 16 h later, cells were transfected 
again for control or Set7 siRNAs using Lipofectamine LTX. Cells were   
cultured in growth medium for an additional 24 h before switching to   
differentiation medium.
GST protein-binding assays
Plasmids encoding GST fusion proteins were transformed into the BL21 
codon plus cells (Agilent Technologies). The cells were grown at 37°C in 
2× YT (yeast extract and tryptone) medium to an optical density of 1.0.   
50 µM IPTG was then added to the culture to induce protein expression. 
After shaking at room temperature for 4–6 h, the cells were harvested, 
and the GST protein was purified with glutathione beads according to 
the manufacturer’s procedure (GE Healthcare). For GST protein-binding 
assays, HEK293T expressing Myc-MyoD lysates were incubated with GST, 
GST-Set7, or GST–Set7-dn beads. After washing three times with GST-
binding buffer, samples were analyzed by SDS-PAGE, and the associated 
proteins were detected by Western blotting.
Immunoblotting and immunostaining
Western  blotting  was  performed  as  previously  described  (Cao  et  al., 
2005) using antibodies against myogenin, MEF2 (Santa Cruz Biotechnol-
ogy, Inc.), MyoD (BD), -Tubulin (Sigma-Aldrich), and phospho–histone 
H3  (Millipore).  The  MF20  antibody,  which  recognizes  striated  muscle-
specific MHC, was obtained from the Developmental Studies Hybridoma 
Bank (University of Iowa). Immunostaining was performed as previously 
described (Chen et al., 2006, 2010). In brief, cells cultured in plates were 
fixed in 4% PFA for 10 min, washed with PBS + 0.1% NP-40, blocked with 
5% goat serum in PBS + 0.1% NP-40 for 1 h at room temperature, and 
incubated with primary antibodies overnight at 4°C. After washing, cells 
were incubated with secondary antibodies for 1 h at room temperature 
and counterstained with DAPI. Myogenic conversion assays in 10T1/2 
cells were performed as previously described (Wang et al., 2004; Cao   
et al., 2005). In brief, 10T1/2 fibroblasts were maintained in DME with 
10% FBS. 1 d before transfection, 10T1/2 cells were plated on 6-well 
format plates at a density of 10
5 cells/well. Lipofectamine LTX reagent 
was used for transfection. 16 h later, cells were switched to differentiation 
medium (DME with 2% horse serum) for 4 d before immunostaining or 
Western blot analysis.
All images were acquired at room temperature from cell culture 
plates by a camera (UFX-DX; Nikon) mounted on an inverted (TE2000; 
Nikon) or upright fluorescence microscope (Microphot SA; Nikon). Digi-
tal fluorescent images were captured at room temperature with a 10× 
(Plan Fluor, air, and NA 0.30), 20× (Plan Fluor, air, and NA 0.45), or 
40× (Plan Fluor, air, and NA 0.60) objective lens using the least pos-
sible exposure to minimize bleaching. The images were processed using 
SPOT (version 3.5.4 for Mac OS [Apple]; Diagnostic Instruments) software 
and were scaled down and cropped in Photoshop (Adobe) to prepare the   
final figures.
Co-IP assays
HEK293T cells were transiently transfected with plasmids encoding the 
epitope-tagged Set7 and/or MyoD proteins as indicated in the figure legends 
with FuGENE 6 (Roche). Cells were harvested 48 h after transfection in 
enhanced in Suv39h1­null MEF cells. We hypothesize that Set7 
might be involved in myoblast fusion processes, as we observe 
substantially fewer multinuclei myotubes in Set7 knockdown or 
Set7­dn–overexpressed C2C12 myoblasts. Several molecules, 
including IL4 and myoferlin, have been implicated in myoblast 
fusion (Horsley et al., 2003; Doherty et al., 2005). However, we 
did not detect a substantial change in the expression levels of 
these proteins during myoblast fusion when Set7 is knocked 
down (unpublished data), implying that other mechanisms are 
likely involved.
In a recent study, Set7 was deleted from the mouse ge­
nome using a gene­targeting approach. A portion of Set7­null 
animals were viable and fertile. It was reported that p53 failed 
to activate its target gene expression in response to DNA dam­
age in Set7­null MEFs (Kurash et al., 2008). Interestingly, about 
half of the Set7­null mice die during embryogenesis, suggesting 
that Set7 is also required for animal development. However, no 
embryonic phenotypic analyses were reported. Our in vivo ex­
periments in zebrafish point to an important role of Set7 in 
muscle development and myofibril assembly. It will be interest­
ing to determine the developmental defects in Set7­null mouse 
embryos, in particular, to assess skeletal muscle development 
and muscle gene expression in future studies.
Collectively, our study provides a mechanism for MyoD 
to activate muscle gene expression and skeletal muscle differ­
entiation, by which MyoD interacts with Set7 to regulate myo­
genesis program, at least in part, through H3­K4 methylation   
at  the  regulatory  regions  of  myogenic  differentiation  genes. 
Given that Set7 expression level was increased during muscle 
differentiation, it is intriguing to speculate that manipulating 
expression levels of Set7 may be a valuable therapeutic ap­
proach of muscle degeneration/regeneration and muscle­related 
diseases, such as Duchenne muscular dystrophy.
Materials and methods
Plasmids and reporter genes
MyoD expression vectors have been previously described (Lu et al., 2000; 
Chen et al., 2006). MyoD mutants were generated through PCR-based   
mutagenesis using the QuickChange kit from Agilent Technologies. All muta-
tions were confirmed by DNA sequencing. The wild-type and mutant Set7 
H297G expression vectors were as previously described (Wang et al., 
2001). The GST-Set7 mutants were previously described (Francis et al., 
2005) and were gifts from R.G. Mirmira (University of Virginia, Charlottesville, 
VA). The PIG (puro internal ribosome entry site GFP empty vector) Set7   
mutants were generated by inserting PCR fragments flanked with EcoRI and 
XhoI into the PIG--multiple cloning site vector. The MCK promoter lucifer-
ase reporter was as previously reported (Chen et al., 2006).
Cell culture, transfection, and muscle differentiation assays
Transfections of 10T1/2 fibroblasts and C2C12 myoblasts were performed 
as previously described (Lu et al., 2000; Chen et al., 2006). Transient 
transfection for luciferase reporter assays, unless otherwise indicated, used 
100 ng of reporter plasmid and 100 ng of each activator plasmid. The 
total amount of DNA per well was kept constant by adding the corresponding   
amount of the expression vector without a cDNA insert. Cytomegalovirus- 
lacZ or cytomegalovirus-GFP was included as an internal control for 
variations in transfection efficiency. All the transfection experiments were 
repeated at least twice in duplicate.
C2C12 myoblast cells were cultured, and myogenic differentiation 
was induced as previously described (Lu et al., 2000) with minor modifi-
cations. In brief, cells were maintained in DME with 10% FBS. We plated 
cells at 50–60% confluence and then performed the transfection the next 
day when they reached 90–100% confluence. We collected cells on the JCB • VOLUME 194 • NUMBER 4 • 2011   564
by  2%  osmium  tetroxide.  Samples  were  stained  with  uranyl  acetate   
(en bloc). Sections were cut in the Microscopy Services Laboratory in the De-
partment of Pathology and Laboratory Medicine at the University of North 
Carolina at Chapel Hill. Images were acquired on a transmission electron 
microscope (Tecnai G2 Spirit BioTWIN; FEI) in the Department of Cell Biol-
ogy at Harvard Medical School.
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lysis buffer composed of PBS containing 0.5% Triton X-100, 1 mM EDTA, 
1 mM PMSF, and complete protease inhibitors (Roche). After a brief soni-
cation and removal of cellular debris by centrifugation, epitope-tagged 
proteins were precipitated with antibodies as indicated and protein A/G 
beads (Santa Cruz Biotechnology, Inc.). The bound proteins were washed 
five times with lysis buffer, resolved by SDS-PAGE, and transferred to poly-
vinylidene difluoride membranes (Bio-Rad Laboratories). Membranes were 
immunoblotted with antibodies as indicated, and proteins were visualized 
with a fluorescence detection system (Odyssey; LI-COR Biosciences).
ChIP assays
ChIP was performed as previously described (Cao and Zhang, 2004) using   
2 µg of either normal mouse or rabbit IgG or antibodies against MyoD (sc304 
and sc760; Santa Cruz Biotechnology, Inc.), Set7 (ab14820; Abcam), 
Suv39h1 (07–550; Millipore), monomethylated H3-K4 (07–436; Millipore), 
and trimethylated H3-K9 (07–442; Millipore). The oligonucleotides used in 
ChIP PCR were MHCIIb promoter forward, 5-CACCCAAGCCGGGAGA-
AACAGCC-3, and reverse, 5-GAGGAAGGACAGGACAGAGGCACC-3;   
MCK  enhancer  forward,  5-AGGGATGAGAGCAGCCACTA-3,  and 
reverse, 5-CAGCCACATGTCTGGGTTAAT-3; myogenin promoter forward, 
5-CCCTGCCCCACAGGGGCTGTG-3, and reverse, 5-ACGCCACA-
GAAACCTGAGCCC-3 (Caretti et al., 2004); MyoD promoter forward, 
5-GCACTGCCACCGATTCATTTG-3, and reverse, 5-CAGGAGGTTTGG-
AGAGAGACTCAAG-3  (Francis  et  al.,  2005);  and  glyceraldehyde 
3-phosphate dehydrogenase (GAPDH) promoter forward, 5-AAGCCAAA-
CTAGCAGCTAGG-3, and reverse, 5-GGGCTAGTCTATCATTGCAG-3 
(Mal and Harter, 2003).
Quantitative RT-PCR
Total RNA was isolated with TRIZOL reagent (Invitrogen). After extraction 
and purification, 1 µg RNA was used as a template for reverse transcrip-
tion with random hexamer primers. All PCR products span the intron region 
of the genes.
Zebrafish
Zebrafish  (Danio  rerio)  embryos  were  obtained  from  the  University  of 
North Carolina, Chapel Hill Zebrafish Aquaculture Core Facility. Embryos 
were injected at cell stage 1–2 with 7–15 pmol zebrafish Set7 (available 
from GenBank/EMBL/DDBJ under accession no. BC076014) morpholino   
(5-GATCACAGCTTGCACCAACCGTTGA-3; Gene Tools, LLC) conjugated 
with FITC, or control morpholino (5-CCTCTTACCTCAGTTACAATTTATA-3). 
In six independent experiments, >350 embryos were injected with control 
MO, and 800 embryos were injected with Set7 MO. In addition, we set 
150–200 noninjected fish aside to serve as additional controls in each 
experiment. Embryos were collected at 18 or 24 h after fertilization for 
further analysis. RT-PCR assays were used to verify the genotyping of Set7 
morphants. In brief, injected fish were collected at 24 h after fertilization, 
and total RNA was extracted using TRIZOL reagent. For RT-PCR, 1 µg 
RNA samples were reverse transcribed to cDNA by using random hexamers 
and Moloney murine leukemia virus reverse transcription (Invitrogen) in a 
20-µl reaction system. 1 µl cDNA pool was used per PCR reaction. The 
sequences of the PCR primers are zebrafish Set7 forward, 5-TCGCTGGT-
CATAAACTGCTG-3,  and  reverse,  5-CTCGTCCTTCTCCACAGCTC-3. 
PCR detected a 386-bp band for the zebrafish Set7 wild-type transcript, 
and a 590-bp mutant band in which the splicing of the pre-mRNA of   
zebrafish Set7 was blocked by MOs.
For immunohistochemistry, embryos were fixed in 4% PFA for 30 
min at room temperature or cold methanol for 3–5 min and then washed 
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MEF2 (1:100; c-21; Hinits and Hughes, 2007), MHC (1:10; A4.1025; 
Developmental Studies Hybridoma Bank; Blagden et al., 1997), slow MHC 
(1:10; F59 and S58; Developmental Studies Hybridoma Bank; Devoto   
et al., 1996), and fast MHC (1:10; EB165; Developmental Studies Hybrid-
oma Bank; Blagden et al., 1997), and diluted in blocking buffer overnight   
at 4°C. After washing, embryos were incubated with an FITC-conjugated 
secondary antibody. Processed samples were mounted in Vectashield (Vec-
tor Laboratories), and the images were acquired with a confocal micro-
scope (FV500 [Olympus]; LSM 5 Pascal [Carl Zeiss]) with a 63× objective 
lens (Plan Apochromat, oil, and NA 1.40; Pathology Microscopy Facility 
at University of North Carolina, Chapel Hill). The images were processed 
using SPOT (version 3.5.4 for Mac OS) software and were scaled down 
and cropped in Photoshop to prepare the final figures.
For  transmission  electronic  microscopy,  control  and  Set7  MO   
embryos were fixed in 2% glutaraldehyde plus 6% sucrose in 0.075 M   
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